Found: 27
Select item for more details and to access through your institution.
Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
- Published in:
- Clinical Cardiology, 1998, v. 21, n. 7, p. 483, doi. 10.1002/clc.4960210707
- By:
- Publication type:
- Article
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.
- Published in:
- European Heart Journal, 2024, v. 45, n. 27, p. 2422, doi. 10.1093/eurheartj/ehae325
- By:
- Publication type:
- Article
Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 16, p. 1408, doi. 10.1093/eurheartj/ehad144
- By:
- Publication type:
- Article
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
- Published in:
- Cardiovascular Drugs & Therapy, 2016, v. 30, n. 5, p. 473, doi. 10.1007/s10557-016-6685-y
- By:
- Publication type:
- Article
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 16, p. 16859, doi. 10.1002/cam4.6310
- By:
- Publication type:
- Article
Evinacumab: Mechanism of action, clinical, and translational science.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 6, p. 1, doi. 10.1111/cts.13836
- By:
- Publication type:
- Article
Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Effect of alirocumab on cataracts in patients with acute coronary syndromes.
- Published in:
- BMC Ophthalmology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12886-023-03012-1
- By:
- Publication type:
- Article
Effect of alirocumab on cataracts in patients with acute coronary syndromes.
- Published in:
- BMC Ophthalmology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12886-023-03012-1
- By:
- Publication type:
- Article
Anti-Anginal and Anti-Ischemic Effects of Mibefradil, a New T-Type Calcium Channel Antagonist.
- Published in:
- Cardiology, 1998, v. 89, p. 23, doi. 10.1159/000047276
- By:
- Publication type:
- Article
Cilazapril with Adjunctive Hydrochlorothiazide.
- Published in:
- Cardiology, 1995, v. 86, n. 1, p. 41, doi. 10.1159/000176829
- By:
- Publication type:
- Article
Cilazapril plus Hydrochlorothiazide: Improved Efficacy without Reduced Safety in Mild to Moderate Hypertension.
- Published in:
- Cardiology, 1994, v. 85, n. 5, p. 311, doi. 10.1159/000176704
- By:
- Publication type:
- Article
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.
- Published in:
- Journal of the American Heart Association, 2018, v. 7, n. 18, p. 1, doi. 10.1161/JAHA.118.009221
- By:
- Publication type:
- Article
Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.
- Published in:
- European Journal of Preventive Cardiology, 2022, v. 29, n. 14, p. 1842, doi. 10.1093/eurjpc/zwac107
- By:
- Publication type:
- Article
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEYOUTCOMES trial.
- Published in:
- European Journal of Preventive Cardiology, 2021, v. 28, n. 1, p. 33, doi. 10.1177/2047487320941987
- By:
- Publication type:
- Article
Alirocumab after acute coronary syndrome in patients with a history of heart failure.
- Published in:
- European Heart Journal, 2022, v. 43, n. 16, p. 1554, doi. 10.1093/eurheartj/ehab804
- By:
- Publication type:
- Article
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
- Published in:
- European Heart Journal, 2020, v. 41, n. 44, p. 4245, doi. 10.1093/eurheartj/ehaa649
- By:
- Publication type:
- Article
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
- Published in:
- European Heart Journal, 2020, v. 41, n. 42, p. 4114, doi. 10.1093/eurheartj/ehaa498
- By:
- Publication type:
- Article
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
- Published in:
- European Heart Journal, 2020, v. 41, n. 24, p. 2248, doi. 10.1093/eurheartj/ehz809
- By:
- Publication type:
- Article
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
- Published in:
- European Heart Journal, 2019, v. 40, n. 33, p. 2801, doi. 10.1093/eurheartj/ehz299
- By:
- Publication type:
- Article
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.
- Published in:
- European Heart Journal, 2016, v. 37, n. 39, p. 2981, doi. 10.1093/eurheartj/ehw292
- By:
- Publication type:
- Article
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
- Published in:
- European Heart Journal, 2015, v. 36, n. 43, p. 2996, doi. 10.1093/eurheartj/ehv370
- By:
- Publication type:
- Article
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
- Published in:
- European Heart Journal, 2015, v. 36, n. 19, p. 1186, doi. 10.1093/eurheartj/ehv028
- By:
- Publication type:
- Article
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II . . .
- Published in:
- BMC Cardiovascular Disorders, 2014, v. 14, n. 1, p. 121, doi. 10.1186/1471-2261-14-121
- By:
- Publication type:
- Article
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
- Published in:
- 2014
- By:
- Publication type:
- journal article